TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7111875

Group type: EXPERIMENTAL
Intervention: Aromatic vapors (eucalyptus, menthol, camphor)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tap water control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intranasal phenylephrine (0.25% solution)
Number of subjects: 24
Study: 30689229

Group type: EXPERIMENTAL
Intervention: Real ABM (Approach Bias Modification)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham ABM
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Real ABM
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Real ABM and Sham ABM
Number of subjects: 56
Study: 30297499

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen (10 mg/kg every 6 hours until 24 hours after the first convulsion if fever >38.0°C)
Number of subjects: 423

Group type: COMPARATOR
Intervention: No antipyretics
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 423
Study: 27092831

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (5 × 10^10 viral particles)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (1 × 10^8 median tissue culture infective dose)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Ad26.ZEBOV
Number of subjects: 87

Group type: COMPARATOR
Intervention: MVA-BN-Filo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 87
Study: 24588860

Group type: EXPERIMENTAL
Intervention: MRI group (GP referral to MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care group (no MRI)
Number of subjects: 0
Study: 22336721

Group type: EXPERIMENTAL
Intervention: Glutamate (0.5 mol/L) injection into the masseter muscle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Co-injection of ketamine (20 mmol/L) with glutamate
Number of subjects: 30
Study: 20200198

Group type: EXPERIMENTAL
Intervention: Interferon beta + inosine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta + placebo
Number of subjects: 0
Study: 17872679

Group type: EXPERIMENTAL
Intervention: Single-dose intrathecal narcotics (ITN) with a combination of 2.5 mg of bupivacaine, 25 microg of fentanyl, and 250 microg of morphine.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural anesthesia (implied control).
Number of subjects: 0
Study: 16078088

Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12384826

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9766253

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test at room temperature (0.1 U per kg of BW, i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin tolerance test under increased ambient temperature for 45 min before and after insulin injection
Number of subjects: 0
Study: 7802070

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified Marshall‐Marchetti‐Krantz urethropexy
Number of subjects: 80
Study: 2969535

Group type: EXPERIMENTAL
Intervention: Acylated plasminogen streptokinase activator complex
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 30355332

Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) approach
Number of subjects: 282

Group type: COMPARATOR
Intervention: Traditional classroom approach
Number of subjects: 282
Study: 26686957

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg per day
Number of subjects: 3104

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg per day
Number of subjects: 3104
Study: 24452393

Group type: EXPERIMENTAL
Intervention: TAS-114 single dose (6, 18, 60, 150, and 300 mg)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: TAS-114 multiple doses (14 days consecutively)
Number of subjects: 35
Study: 22458335

Group type: EXPERIMENTAL
Intervention: Alcohol-dependent patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 20920997

Group type: EXPERIMENTAL
Intervention: XELIRI (capecitabine and irinotecan)
Number of subjects: 450

Group type: COMPARATOR
Intervention: FOLFIRI (infusional 5-fluorouracil and irinotecan)
Number of subjects: 450
Study: 18683218

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg monthly for 1 year)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Observation (no zoledronic acid)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control
Number of subjects: 163
Study: 15914986

Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste
Number of subjects: 15

Group type: COMPARATOR
Intervention: Fluoride-free toothpaste
Number of subjects: 15
Study: 15086479

Group type: EXPERIMENTAL
Intervention: High dose dialysis
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Standard dose dialysis
Number of subjects: 1846
Study: 10667876

Group type: EXPERIMENTAL
Intervention: 20-minute session emphasizing the importance of screening for domestic violence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated topic session (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in knowledge assessment
Number of subjects: 0
Study: 9293855

Group type: EXPERIMENTAL
Intervention: Fludarabine (FLU) as salvage chemotherapy, 25 mg/m2 for 5 consecutive days, repeated every 28 days for a maximum of 6 cycles.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Alpha-interferon (alpha-IFN) maintenance therapy, 3x10^6 units 3 times per week until disease progression.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Alpha-interferon (alpha-IFN) maintenance therapy vs no further therapy after FLU response.
Number of subjects: 137
Study: 8517952

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg/kg per h)
Number of subjects: 91
Study: 3771289

Group type: EXPERIMENTAL
Intervention: Training effect observed during the 6-week period
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coefficient of variation of intra-individual differences
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Coefficient of variation of inter-individual differences
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Measurement error
Number of subjects: 5
Study: 2783492

Group type: EXPERIMENTAL
Intervention: Acupuncture‐like TENS treatment (10-minute treatment bilaterally to five acupuncture points on the auricle)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo pill)
Number of subjects: 15
Study: 31783028

Group type: EXPERIMENTAL
Intervention: 2% Vitamin C solution (VCS)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 5% Sodium thiosulfate solution (STS)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal saline solution (NS)
Number of subjects: 240
Study: 30641692

Group type: EXPERIMENTAL
Intervention: Probiotic supplements (7 viable strains: Lactobacillus, Bifidobacterium, and Streptococcus) for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 60
Study: 28750001

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 25515658

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dosage of 30 Gy in 10 fractions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 156
Study: 23427972

Group type: EXPERIMENTAL
Intervention: Multisensory teaching approach
Number of subjects: 120
Study: 21332742

Group type: EXPERIMENTAL
Intervention: 1% citric acid solution (pH 2.3) for 20 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-acid surface (control)
Number of subjects: 10
Study: 19833271

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D)
Number of subjects: 40
Study: 16789982

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Nicomorphine
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Ketobemidone
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 124655

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 124655

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 124655

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 124655

Group type: COMPARATOR
Intervention: Dextropropoxiphene
Number of subjects: 124655

Group type: COMPARATOR
Intervention: ASA and Codeine combination
Number of subjects: 124655
Study: 15334532

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study: 11314290

Group type: EXPERIMENTAL
Intervention: Hans-Rudolph facemask
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mouthpiece apparatus
Number of subjects: 30
Study: 9143543

Group type: EXPERIMENTAL
Intervention: Dynamic capillaroscopy
Number of subjects: 35
Study: 7954555

Group type: EXPERIMENTAL
Intervention: Continuous intravenous isosorbide dinitrate
Number of subjects: 30

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 30
Study: 2440203

Group type: EXPERIMENTAL
Intervention: Specific immunoglobulin against hepatitis A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common commercial immunoglobulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonimmunized subjects
Number of subjects: 0
Study: 30019829

Group type: EXPERIMENTAL
Intervention: Palatal approach (study group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Buccal approach (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 28844559

Group type: EXPERIMENTAL
Intervention: Active high-frequency rTMS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham high-frequency rTMS
Number of subjects: 58
Study: 25500887

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) 2.5 mg/kg intravenously followed by pegylated G-CSF 6 mg subcutaneously every 2 weeks for 6 doses
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) and pegylated G-CSF
Number of subjects: 25
Study: 23664121

Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Social situations
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peer cannabis use
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reasons for use
Number of subjects: 30
Study: 21395446

Group type: EXPERIMENTAL
Intervention: Weekly Fast Facts and Concept (FFAC) e‐mails, 32 e‐mails over 32 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Weekly Fast Facts and Concept (FFAC) e‐mails
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no e‐mails)
Number of subjects: 82
Study: 17935855

Group type: EXPERIMENTAL
Intervention: Modified Insertion Technique (MIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard Insertion Technique (SIT)
Number of subjects: 54
Study: 17190104

Group type: EXPERIMENTAL
Intervention: 4G-beta-D-galactosylsucrose (lactosucrose; LS) 6.0 g twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (maltose; 6.0 g twice daily)
Number of subjects: 17
Study: 14707396

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily (o.d.)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Misoprostol 200 microg twice daily (b.i.d.)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.d.
Number of subjects: 515

Group type: COMPARATOR
Intervention: Misoprostol 200 microg b.i.d.
Number of subjects: 515
Study: 10713292

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-energy breakfast
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-energy breakfast
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ad libitum lunch after exercise and breakfast conditions
Number of subjects: 11
Study: 9253878

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 2053434

Group type: EXPERIMENTAL
Intervention: Occlusal adjustment (T group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 6837813

Group type: EXPERIMENTAL
Intervention: School-based practice with enriched dental health education
Number of subjects: 1800

Group type: COMPARATOR
Intervention: School-based practice without enriched dental health education
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Private practitioners in the community with enriched dental health education
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Private practitioners in the community without enriched dental health education
Number of subjects: 1800
Study: 30665714

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) program with EAP training (N=49)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cognitive remediation (CR) program without EAP training (N=54)
Number of subjects: 103
Study: 29990524

Group type: EXPERIMENTAL
Intervention: To-Go Group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 53
Study: 26661322

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 25458331

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2mg/day for 12 months
Number of subjects: 86
Study: 22380537

Group type: EXPERIMENTAL
Intervention: Yogurt
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water
Number of subjects: 40
Study: 20429852

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18382077

Group type: EXPERIMENTAL
Intervention: exercise + MV
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MV
Number of subjects: 39

Group type: COMPARATOR
Intervention: control
Number of subjects: 39
Study: 16045394

Group type: EXPERIMENTAL
Intervention: Happiness interventions (3 of them)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Plausible control exercise
Number of subjects: 6
Study: 12008944

Group type: EXPERIMENTAL
Intervention: HSP70‐1 nucleotide 190
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: HSP70‐2 nucleotide 1267
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: HSP70‐hom nucleotide 2437
Number of subjects: 338
Study: 10023867

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 0.5 mg/kg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1.0 mg/kg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 2.0 mg/kg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) (any dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no ASA)
Number of subjects: 12
Study: 7802127

Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Face-valid questions about fixity of obsessive-compulsive beliefs
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: ICD-10 subcategories
Number of subjects: 431
Study: 2218873

Group type: EXPERIMENTAL
Intervention: Cystgastrostomy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cystjejunostomy
Number of subjects: 98
Study: 401759

Group type: EXPERIMENTAL
Intervention: Trental 400 (400 mg Pentoxifylline per tablet), 3 tablets daily for 3 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparative formulation (2.4 mg adenosine per tablet), 3 tablets daily for 3 months
Number of subjects: 52
Study: 31969713

Group type: EXPERIMENTAL
Intervention: Lidocaine 5% spray, 1-2 applications (0.1-0.2 ml) for 8 weeks, containing 5-10 mg of lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (alcohol 40% spray), 1-2 applications (0.1-0.2 ml) for 8 weeks
Number of subjects: 150
Study: 31196037

Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program (12 lessons)
Number of subjects: 6300

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6300
Study: 28546852

Group type: EXPERIMENTAL
Intervention: Resveratrol (1000 mg/day for 28 days)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 4
Study: 24684297

Group type: EXPERIMENTAL
Intervention: batroxobin with continuous TCD monitoring
Number of subjects: 90

Group type: COMPARATOR
Intervention: batroxobin without continuous TCD monitoring
Number of subjects: 90
Study: 23532686

Group type: EXPERIMENTAL
Intervention: ASA+ER‐DP 25 mg/200 mg BID alone (Treatment A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ASA+ER‐DP 25 mg/200 mg BID + omeprazole 80 mg QD (Treatment B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole 80 mg QD alone (Treatment C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg QD + ASA+ER‐DP 25 mg/200 mg BID (Treatment D)
Number of subjects: 60
Study: 19836206

Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Western Ontario Rotator Cuff index (WORC)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Oxford Shoulder Scale (OSS)
Number of subjects: 121
Study: 19071979

Group type: EXPERIMENTAL
Intervention: Take‐home methadone doses contingent on cocaine‐ and opiate‐negative results (THM)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Take‐home methadone doses for cocaine‐ and opiate‐negative results and monetary‐based vouchers contingent on cocaine‐negative urinalysis results (THM + V)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care only (UC)
Number of subjects: 78
Study: 17286121

Group type: EXPERIMENTAL
Intervention: Locomotion around the scene (viewpoint changes from 40 degrees to 360 degrees in experiment 1; 36 degrees to 180 degrees in experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locomotion around the scene (viewpoint changes from 36 degrees to 180 degrees in experiment 2)
Number of subjects: 0
Study: 12817520

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg qd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen 500 mg bid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib (5-500 mg single doses and 25-150 mg multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib (up to 150 mg qd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 0
Study: 11165311

Group type: EXPERIMENTAL
Intervention: Sodium lactate administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1355618

Group type: EXPERIMENTAL
Intervention: Beclomethasone inhalations before fenoterol inhalations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fenoterol inhalations
Number of subjects: 40
Study: 6516935

Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy without imagery (RET)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy with imagery (REI)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy (RET) and Rational-emotive therapy with imagery (REI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Relationship-oriented counseling (ROC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waiting-list control (WLC)
Number of subjects: 59
Study: 30685386

Group type: EXPERIMENTAL
Intervention: PLWH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 29765212

Group type: EXPERIMENTAL
Intervention: Conjugated Linoleic Acid (CLA) supplement, 3.2 g daily for 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo, 3.2 g daily for 6 weeks
Number of subjects: 90
Study: 27189289

Group type: EXPERIMENTAL
Intervention: AST-120 (6 g/day) for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 24374936

Group type: EXPERIMENTAL
Intervention: Fibrillary astrocytes in schizophrenia
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gemistocytic astrocytes in schizophrenia
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fibrillary astrocytes in bipolar disorder, major depression, and normal controls
Number of subjects: 67

Group type: COMPARATOR
Intervention: Gemistocytic astrocytes in bipolar disorder, major depression, and normal controls
Number of subjects: 67
Study: 23607203

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (including pre‐ and postoperative irradiation, surgery, adjuvant chemotherapy)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Surgery with adjuvant chemotherapy
Number of subjects: 296
Study: 20105041

Group type: EXPERIMENTAL
Intervention: P1+ (preserved first-phase insulin secretion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: P1- (no first-phase insulin secretion)
Number of subjects: 20
Study: 16257791

Group type: EXPERIMENTAL
Intervention: 3 months' androgen deprivation (3.6 mg goserelin subcutaneously every month and 250 mg flutamide orally three times a day)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: 6 months' androgen deprivation (same regimen as above)
Number of subjects: 818

Group type: COMPARATOR
Intervention: No androgen deprivation (radiotherapy alone: 66 Gy in 33 fractions of 2 Gy per day over 6.5‐7.0 weeks)
Number of subjects: 818
Study: 14717260

Group type: EXPERIMENTAL
Intervention: Comprehensive Child Development Program (CCDP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (families on AFDC)
Number of subjects: 240
Study: 9633847

Group type: EXPERIMENTAL
Intervention: Multiple cycles of high-dose chemotherapy with hematopoietic support (colony-stimulating factors and peripheral blood progenitor cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple cycles of high-dose chemotherapy
Number of subjects: 0